Amphastar Announces Approval for Sodium Nitroprusside Injection, USP
December 19, 2017 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of its...
Amphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USP
November 29, 2017 14:50 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of two...
Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 20, 2017 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017
November 08, 2017 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September...
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2017
October 31, 2017 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2017, ended...
Amphastar Announces Approval for Neostigmine Methylsulfate Injection, USP
September 25, 2017 18:50 ET
|
Amphastar Pharmaceuticals Inc.
RANCHO CUCAMONGA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of its...
Amphastar Pharmaceuticals Receives FDA Approval for Sodium Bicarbonate Injection
September 20, 2017 16:22 ET
|
Amphastar Pharmaceuticals Inc.
RANCHO CUCAMONGA, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on September 19, 2017, the U.S. Food and Drug Administration (“FDA”) granted...
Amphastar Pharmaceuticals to Present at the 2017 Wells Fargo Securities Healthcare Conference
August 30, 2017 06:00 ET
|
Amphastar Pharmaceuticals Inc.
RANCHO CUCAMONGA, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2017 Wells Fargo...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2017
August 09, 2017 16:05 ET
|
Amphastar Pharmaceuticals Inc.
RANCHO CUCAMONGA, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30,...
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9, 2017
August 02, 2017 06:00 ET
|
Amphastar Pharmaceuticals Inc.
RANCHO CUCAMONGA, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2017, ended June...